CULLINAN THERAPEUTICS, INC. Other
Cover page items of the 10-K and 10-Q that have no other home: a security other than the listed stock or a bond, a check box that differs from the latest cover, or a figure not in the Balance Sheet › Equity tabs. Newest first, as filed.
- 2025-05-08: Form 10-Q; Item Smaller reporting company; As filed No.
- 2024-11-07: Form 10-Q; Item Emerging growth company; As filed Yes.
- 2024-08-08: Form 10-Q; Item Emerging growth company; As filed Yes.
- 2024-05-15: Form 10-Q; Item Emerging growth company; As filed Yes.
| Filed | Form | Item | As filed |
|---|---|---|---|
| 2025-05-08 | 10-Q | Smaller reporting company | No |
| 2024-11-07 | 10-Q | Emerging growth company | Yes |
| 2024-08-08 | 10-Q | Emerging growth company | Yes |
| 2024-05-15 | 10-Q | Emerging growth company | Yes |
| 2024-03-14 | 10-K | Emerging growth company | Yes |
| 2023-11-08 | 10-Q | Emerging growth company | Yes |
| 2023-08-10 | 10-Q | Emerging growth company | Yes |
| 2023-05-11 | 10-Q | Emerging growth company | Yes |
| 2023-03-09 | 10-K | Emerging growth company | Yes |
| 2022-11-14 | 10-Q | Emerging growth company | Yes |
| 2022-08-10 | 10-Q | Emerging growth company | Yes |
| 2022-05-16 | 10-Q | Emerging growth company | Yes |
| 2022-03-17 | 10-K | Emerging growth company | Yes |
| 2021-11-09 | 10-Q | Emerging growth company | Yes |
| 2021-08-10 | 10-Q | Emerging growth company | Yes |
| 2021-05-14 | 10-Q | Stock registered under Section 12(b) | Common Stock, par value $0.0001 per share · CGEM · NASDAQ |
| 2021-05-14 | 10-Q | Emerging growth company | Yes |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |